China's National Medical Products Association Approves AstraZeneca's Fasenra (Benralizumab) For The Maintenance Treatment Of Patients 12 Years And Older With Severe Eosinophilic Asthma
Portfolio Pulse from Benzinga Newsdesk
China's National Medical Products Association has approved AstraZeneca's Fasenra (Benralizumab) for the maintenance treatment of severe eosinophilic asthma in patients aged 12 and older.
August 20, 2024 | 8:58 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's Fasenra has been approved in China for treating severe eosinophilic asthma, potentially expanding its market reach and boosting sales in the region.
The approval of Fasenra in China opens up a significant market for AstraZeneca, likely leading to increased sales and revenue. This regulatory milestone is a positive development for the company, enhancing its product portfolio in a major market.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90